Next Article in Journal
One Year Outcomes Following Transplantation with COVID-19-Positive Donor Hearts: A National Database Cohort Study
Previous Article in Journal
Apolipoprotein B and Lipid Profile in Italian Children and Adolescents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Achieving Cardiovascular Risk Management Goals and Patient Quality of Life

by
Agata Kosobucka-Ozdoba
1,†,
Łukasz Pietrzykowski
1,*,†,
Piotr Michalski
1,
Jakub Ratajczak
1,
Klaudyna Grzelakowska
2,
Michał Kasprzak
2,
Jacek Kubica
2 and
Aldona Kubica
1
1
Department of Cardiac Rehabilitation and Health Promotion, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland
2
Department of Cardiology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Cardiovasc. Dev. Dis. 2024, 11(2), 45; https://doi.org/10.3390/jcdd11020045
Submission received: 31 December 2023 / Revised: 18 January 2024 / Accepted: 29 January 2024 / Published: 31 January 2024
(This article belongs to the Section Epidemiology, Lifestyle, and Cardiovascular Health)

Abstract

:
(1) Background: Eliminating or reducing the severity of modifiable risk factors of cardiovascular disease (CVD) and undertaking health-promoting behaviors is the basis for prevention. (2) Methods: This study included 200 subjects without a history of CVD, aged 18 to 80 years, who had been diagnosed with hypertension, hypercholesterolemia, or diabetes 6 to 24 months before study enrolment. (3) Results: The median 10-year CV risk assessed by the SCORE2 and SCORE2-OP algorithms was 3.0 (IQR 1.5–7.0). An increase in mean cardiovascular risk in the range from low and moderate to very high was associated with a decrease in quality of life both in individual subscales and the overall score. The median number of controlled risk factors was 4.0 (IQR 3.0–5.0). As the mean number of controlled risk factors increased, the quality of life improved in both of HeartQoL questionnaire subscales (emotional p = 0.0018; physical p = 0.0004) and the overall score (global p = 0.0001). The median number of reported health-promoting behaviors undertaken within 3 years before study enrolment was 3.0 (IQR 2.0–4.0). The highest quality of life in each of the studied dimensions was found in people who reported undertaking three health-promoting behaviors. (4) Conclusions: Controlling CVD risk factors and undertaking health-promoting behaviors has a positive impact on the quality of life of patients without a history of atherosclerotic CVD.

1. Introduction

The achievement of treatment goals for the control of risk factors is the basis of cardiovascular disease (CVD) treatment [1,2] and prevention [3]. Assessing the quality of life of chronically ill patients is considered a necessary element in a comprehensive health assessment. It can and should serve as an additional source of information on the physical, mental, and social well-being of the patient [3,4,5,6]. Higher quality of life is associated with more effective control of risk factors, better functioning, and prognosis [4,5,6,7,8]. Little is known about the relationship between the efficacy of cardiovascular risk factors’ management and patients’ quality of life, particularly those without clinically evident atherosclerotic cardiovascular disease. Therefore, we undertook a study of the relationship between the achievement of therapeutic targets for cardiovascular risk factors and both the health-promoting behaviors undertaken and the quality of life in people without diagnosed CVD.

2. Materials and Methods

This study included 200 subjects without a history of CVD, aged 18 to 80 years, who had been diagnosed with hypertension, hypercholesterolemia, or diabetes 6 to 24 months before study enrolment. The characteristics of the study group are presented in Table 1 and Table 2.
This study was designed as a multi-center prospective registry, approved by the Ethics Committee of Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz (study approval reference number KB 586/2017). Individual patients were invited to this study after prior identification of inclusion criteria fulfillment based on medical records in primary care facilities. In compliance with the principles of good clinical practice and the Declaration of Helsinki, each patient gave written informed consent to participate in this study. During the only visit scheduled for this study, venous blood samples were collected and anthropometric measurements (height, body weight, waist circumference) were taken. Measures of cardiovascular (CV) risk factors were assessed: arterial blood pressure, body mass index (BMI), waist circumference, physical activity, smoking status, serum concentrations of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and fasting plasma glucose. A history of health-promoting behaviors during the 3 years before inclusion in this study was collected: dietary changes, weight reduction, increased physical activity, smoking cessation, and decreased alcohol consumption. Furthermore, cardiovascular risk was assessed using the Systematic Coronary Risk Evaluation 2 (SCORE2) and Systematic Coronary Risk Evaluation 2—Older Persons (SCORE2-OP) algorithms. In addition, quality of life was assessed using the HeartQoL questionnaire.
Arterial blood pressure was measured twice in a sitting position using semi-automatic sphygmomanometers. Diagnosis and classification of arterial hypertension were performed based on the current criteria of the European Society of Cardiology [9].
A current smoking status was verified by assessing the concentration of carbon monoxide in exhaled air (Bedfont Scientific Micro+ Smokerlyzer monitor). A result of >10 ppm was considered indicative of active smoking.
Measurement of serum TC, HDL-C, non-HDL-C, LDL-C, TG, and fasting blood glucose in venous blood samples was performed using the Alinity ci-series analyzer (Abbott, Wiesbaden, Germany).
Physical activity was assessed based on patients’ answers to the following question: ‘Which of the following terms best describes your non-professional activity?’ with 4 possible answers: (1) ‘I do not engage in any physical activity other than professional work’; (2) ‘Most of the time only light physical activity’; (3) ‘Intense physical activity at least 20 min 1–2 times a week’; (4) ‘20 min of intense physical activity more often than twice a week’. Responses 3 and 4 were considered to be the appropriate level of physical activity.
The risk factors within which the therapeutic target was achieved were defined as a controlled risk factors using the following criteria:
  • Ideal blood pressure: systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg;
  • Ideal BMI: BMI 20.0–24.9 kg/m2; however, patients with BMI < 20.0 kg/m2 were not included in the analysis of uncontrolled risk factors with regards to BMI (11 patients);
  • Ideal waist circumference: <80 cm for women and <94 cm for men;
  • Regular physical activity: intense physical activity for 20 min or more at least 1–2 times a week;
  • Non-smoker: the declared status of a non-smoker was objectively confirmed by a concentration of carbon monoxide in exhaled air ≤10 ppm;
  • Normal LDL-C: <2.6 mmol/L (<100 mg/dL);
  • Normal TG: <1.7 mmol/L (<150 mg/dL);
  • Normal fasting glucose: <100 mg/dL (<5.6 mmol/L).
The health-promoting behaviors that the subjects undertook over a period of 3 years were assessed based on subjective declarations. Respondents answered the question ‘Have you used any of these methods in recent years to reduce your risk of developing ischemic heart disease?’:
  • Dietary changes (decrease in salt intake, decrease in fat intake, change in the type of fat consumed, decrease in meals’ caloric content, increase in fruit and vegetable intake, increase in fish intake, increase in fatty fish intake, decrease in sugar intake);
  • Weight reduction (with diet, by participating in regular physical exercise, using weight loss medications);
  • Increased physical activity (as part of a professionally established exercise program, by participating in fitness club activities, increasing physical activity on most days of the week, jogging or hiking);
  • Smoking cessation (abstinence, reduction in the number of cigarettes smoked, advice in a smoking cessation clinic, use of nicotine replacement therapy);
  • Decreased alcohol consumption.
For each of the methods, the respondent could answer: (1) ‘No’, (2) ‘Yes’, or (3) ‘I don’t know’. Only the answer ‘Yes’ was considered to indicate a health-promoting behavior in individual categories.
CV risk was assessed using the SCORE2 and SCORE2-OP algorithms according to the guidelines of the European Society of Cardiology with adjusted norms for Poland as a high-risk country based on SCORE2 and SCORE2-OP risk regions [10,11]. Using the SCORE2 and SCORE2-OP algorithms, the 10-year risk of CV death in apparently healthy subjects was calculated taking into account gender, age, non-HDL cholesterol concentration, systolic blood pressure, and smoking status. Cardiovascular risk was expressed as a percentage and then defined as low or moderate, high, or very high based on ESC guidelines [10,11]. Patients with diagnosed diabetes (n = 38) were excluded from CV risk assessment due to the lack of complete data required for assessment with the use of SCORE2-Diabetes, an algorithm specifically dedicated to this group [12].
Quality of life was assessed using the standardized HeartQoL questionnaire, a tool recommended by the European Association of Preventive Cardiology (EAPC) [4,13,14,15]. The HeartQoL questionnaire consists of 14 questions that assess the quality of life in the emotional (HeartQoL emotional) and physical (HeartQoL physical) dimensions, as well as globally (HeartQoL global). In each question, you can score from 0 to 3 points. A higher score indicates a better quality of life. Quality of life in individual subscales and as a global score was calculated based on the mean scores from individual questions.
The statistical analysis was carried out using the Statistica 13.0 package (TIBCO Software Inc., Palo Alto, CA, USA). Categorical variables were expressed as the number and the percentage. Continuous variables were presented as means with standard deviations or medians with interquartile range. The Shapiro–Wilk test demonstrated a non-normal distribution of the investigated continuous variables. Therefore, non-parametric tests were used for statistical analysis. Comparisons between two groups were performed with the Mann–Whitney unpaired rank sum test. For comparisons between more groups, the Kruskal–Wallis one-way analysis of variance was used. To assess the relationship between two quantitative variables, Spearman’s rank correlation was used. To identify independent predictors of HeartQoL questionnaire results, multiple linear regression analysis was performed. Results were considered significant at p < 0.05.

3. Results

3.1. Cardiovascular Risk

The median 10-year CV risk assessed by the SCORE2 and SCORE2-OP algorithms was 3.0 (IQR 1.5–7.0). An increase in mean cardiovascular risk in the range from low and moderate to very high was associated with a decrease in quality of life both in individual subscales and the overall score (Figure 1). This relationship was also confirmed by Spearman’s negative correlation (HeartQoL emotional R = −0.3989, p < 0.0001; HeartQoL physical: R = −0.4913, p < 0.0001; HeartQoL global R = −0.4907, p < 0.0001).

3.2. Controlled Risk Factors

The median number of controlled risk factors in the study population was 4.0 (IQR 3.0–5.0). It was found that as the mean number of controlled risk factors increased, the quality of life improved in each of the studied dimensions (Figure 2).
Individuals who reported regular physical activity and who were characterized by blood glucose, arterial blood pressure, and waist circumference within the normal range had higher scores on both subscales and the overall HeartQoL score in the univariate analysis (Table 3). The other risk factors assessed separately did not differentiate the study population in terms of quality of life.

3.3. Reported Undertaken Health-Promoting Behaviors

The median number of reported health-promoting behaviors undertaken within 3 years before study enrolment was 3.0 (IQR 2.0–4.0). The percentage of patients undertaking specific health-promoting behaviors is shown in Table 1. The highest quality of life in each of the studied dimensions was found in people who reported undertaking three health-promoting behaviors (Figure 3).
Higher quality of life was seen in those who reported dietary changes (HeartQoL physical and the overall score) and in those who reported increased physical activity (both subscales and the HeartQoL global score). On the other hand, those who reported reduced alcohol consumption had a lower quality of life based on the HeartQoL emotional subscale (Table 4).

4. Discussion

According to World Health Organization (WHO) reports, non-communicable diseases, including cardiovascular diseases, constitute a serious health, social, and economic problem. Taking action to eliminate modifiable risk factors for these diseases is of interest to many institutions. As one of the leading causes of disease and premature death worldwide, cardiovascular diseases require prevention as well as early diagnosis and treatment. Reducing the prevalence of non-communicable diseases and the high mortality associated with them is one of the main objectives of improving the health situation planned by the WHO for the coming years [16].
Adopting health-promoting behaviors, such as regular physical activity, changing dietary habits, or controlling blood pressure values, as well as eliminating risky behaviors such as smoking, may not only affect the health and quality of life of individual patients but also lead to beneficial social and economic consequences [17].
Some authors suggest that a higher quality of life may be associated with more effective control of CV risk factors, better functioning, and improved prognosis in chronic diseases [8,18,19,20,21,22]. There are also reports on the impact of specific risk factors on the prognosis and treatment process of ischemic heart disease [4,5,6,7,8,23,24,25,26]. The impact of chronic diseases on the patient’s well-being and quality of life depends, among other things, on the degree of disease progression and the severity of symptoms [8,27,28]. Nevertheless, to the best of our knowledge, our study is the first to answer the question of whether and to what extent achieving treatment goals for controlling CVD risk factors and undertaking health-promoting behaviors affects the quality of life of people without clinically evident atherosclerotic CVD.
In subjects without clinically evident CVD, we found that increased CV risk in the range from low and moderate to very high assessed using the SCORE2 and SCORE2-OP algorithms was associated with decreased quality of life on both the individual subscales and the overall HeartQoL score. We established that as the number of controlled risk factors increased, quality of life improved in each of the studied dimensions. The analysis demonstrated that regular physical activity, normal fasting glucose, correct waist circumference, and correct blood pressure were all independent single risk factors affecting the quality of life assessed with the HeartQoL global scale, as well as both emotional and physical subscales. This appears to be consistent with the results confirming that the control of risk factors has a positive impact on many aspects of the patient’s functioning, including quality of life [8,28,29,30]. Positive effects of physical activity on lowering systolic and diastolic blood pressure and improving quality of life have also been described [31,32]. These correlations highlight the importance and usefulness of quality of life assessment in patients with high CV risk or with clinically evident CVD. The adverse effect of increasing BMI on overall functioning and physical activity levels, especially in patients with ischemic heart disease and morbid obesity, has been previously described by A. Oreopoulos et al. [7]; however, we were unable to show an association between quality of life and BMI, while we did show such an association with waist circumference.
We found an interesting correlation between beneficial changes in health-promoting behaviors reported by patients and the HeartQoL scores. The lowest quality of life was found in patients who made no lifestyle changes at all and those who made the most lifestyle changes. The highest quality of life in each studied dimension was found in people who reported undertaking a moderate number of health-promoting behaviors. It can be assumed that taking on too many health-promoting behaviors is associated with increased pressure and stress imposed by the patient on themself. A similar relationship is observed in the group of patients suffering from orthorexia, where it is noted that increased attention to diet does not translate into better well-being and may be a source of anxiety [33]. The best quality of life was recorded in the group with an average number of health-promoting behaviors. The relationship between quality of life and beneficial health-promoting behaviors is probably two-way. On the one hand, controlling risk factors and undertaking health-promoting behaviors can improve quality of life, and on the other hand, good quality of life facilitates the implementation of expected health-promoting behaviors [34].
As expected, individual health-promoting behaviors associated with higher quality of life turned out to be increased physical activity and dietary changes. Physical activity is a factor that significantly influences many aspects of a CVD patient’s life and improves their prognosis [24,26]. Physical activity is strongly associated with the functioning of patients with ischemic heart disease [5] and aerobic exercise helps to reduce the impact of adverse risk factors and improves the declared quality of life [6], which is consistent with our results. A diet aimed at reducing excess body weight can be found in all guidelines for the prevention and treatment of cardiovascular diseases [1,2,34]. It has been proven that, as in our study group, a calorie-restricted diet [35] and the introduction of dietary rules based on the elimination of highly processed fats, the consumption of fish and seafood, and adequate amounts of fruit, vegetables, and fiber [23,25] has a beneficial effect on the reduction of risk factors and improves the quality of life of patients. Unexpectedly, reducing alcohol consumption negatively affected the emotional component of the QoL assessment in the population we studied. It is worth noting that similar results were obtained by T. Thara Govindaraju et al. [29].
Limitations of this study are the limited number of patients included and the absence of long-term follow-up, along with the imprecise definitions we used of physical activity and declared health-promoting behaviors. Furthermore, this study was also limited by a lack of complete data to assess the diabetic population using the SCORE2-Diabetes algorithm.

5. Conclusions

The quality of life is affected by the health-promoting behaviors undertaken, depending on their number. The highest quality of life in each of the studied dimensions was found in people who reported undertaking a moderate number of health-promoting behaviors. On the other hand, extreme behaviors, i.e., not undertaking any health-promoting behaviors or undertaking a very large number of them, were associated with a poorer quality of life.

Author Contributions

Conceptualization, A.K., Ł.P. and A.K.-O.; methodology, A.K.; formal analysis, M.K. and Ł.P.; investigation, A.K., Ł.P. and A.K.-O.; resources, Ł.P. and P.M.; data curation, A.K.-O., Ł.P., P.M., J.R. and A.K.; writing—original draft preparation, A.K.-O. and Ł.P.; writing—review and editing, A.K. and K.G.; visualization, M.K. and Ł.P.; supervision, J.K.; project administration, A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nicolaus Copernicus University in Toruń Collegium Medicum, Bydgoszcz, Poland (study approval reference number: KB 586/2017, date: 19 September 2017).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The data presented in this study are available from all authors.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Byrne, R.A.; Rossello, X.; Coughlan, J.J.; Barbato, E.; Berry, C.; Chieffo, A.; Claeys, M.J.; Dan, G.-A.; Dweck, M.R.; Galbraith, M.; et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Eur. Heart J. 2023, 44, 3720–3826. [Google Scholar] [CrossRef]
  2. Marx, N.; Federici, M.; Schütt, K.; Müller-Wieland, D.; Ajjan, R.A.; Antunes, M.J.; Christodorescu, R.M.; Crawford, C.; Di Angelantonio, E.; Eliasson, B.; et al. 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Eur. Heart J. 2023, 44, 4043–4140. [Google Scholar] [CrossRef]
  3. Hansen, T.B.; Thygesen, L.C.; Zwisler, A.D.; Helmark, L.; Hoogwegt, M.; Versteeg, H.; Höfer, S.; Oldridge, N. Self-Reported Health-Related Quality of Life Predicts 5-Year Mortality and Hospital Readmissions in Patients with Ischaemic Heart Disease. Eur. J. Prev. Cardiol. 2015, 22, 882–889. [Google Scholar] [CrossRef] [PubMed]
  4. Spinka, F.; Aichinger, J.; Wallner, E.; Brecht, S.; Rabold, T.; Metzler, B.; Zweiker, R.; Lang, I.; Delle Karth, G. Functional Status and Life Satisfaction of Patients with Stable Angina Pectoris in Austria. BMJ Open 2019, 9, e029661. [Google Scholar] [CrossRef]
  5. Pattyn, N.; Vanhees, L.; Cornelissen, V.A.; Coeckelberghs, E.; De Maeyer, C.; Goetschalckx, K.; Possemiers, N.; Wuyts, K.; Van Craenenbroeck, E.M.; Beckers, P.J. The Long-Term Effects of a Randomized Trial Comparing Aerobic Interval versus Continuous Training in Coronary Artery Disease Patients: 1-Year Data from the SAINTEX-CAD Study. Eur. J. Prev. Cardiol. 2016, 23, 1154–1164. [Google Scholar] [CrossRef]
  6. Reriani, M.; Flammer, A.J.; Duhé, J.; Li, J.; Gulati, R.; Rihal, C.S.; Lennon, R.; Tilford, J.M.; Prasad, A.; Lerman, L.O.; et al. Coronary Endothelial Function Testing May Improve Long-Term Quality of Life in Subjects with Microvascular Coronary Endothelial Dysfunction. Open Heart 2019, 6, e000870. [Google Scholar] [CrossRef]
  7. Oreopoulos, A.; Padwal, R.; McAlister, F.A.; Ezekowitz, J.; Sharma, A.M.; Kalantar-Zadeh, K.; Fonarow, G.C.; Norris, C.M. Association between Obesity and Health-Related Quality of Life in Patients with Coronary Artery Disease. Int. J. Obes. 2010, 34, 1434–1441. [Google Scholar] [CrossRef]
  8. Kubica, A.; Pietrzykowski, Ł.; Michalski, P.; Kasprzak, M.; Ratajczak, J.; Siódmiak, J.; Fabiszak, T.; Buczkowski, K.; Krintus, M.; Jankowski, P. The Occurrence of Cardiovascular Risk Factors and Functioning in Chronic Illness in the Polish Population of EUROASPIRE V. Cardiol. J. 2022, VM/OJS/J/91163. [Google Scholar] [CrossRef] [PubMed]
  9. Galiè, N.; Humbert, M.; Vachiery, J.-L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016, 37, 67–119. [Google Scholar] [CrossRef] [PubMed]
  10. SCORE2 working group and ESC Cardiovascular risk collaboration; Hageman, S.; Pennells, L.; Ojeda, F.; Kaptoge, S.; Kuulasmaa, K.; de Vries, T.; Xu, Z.; Kee, F.; Chung, R.; et al. SCORE2 Risk Prediction Algorithms: New Models to Estimate 10-Year Risk of Cardiovascular Disease in Europe. Eur. Heart J. 2021, 42, 2439–2454. [Google Scholar] [CrossRef]
  11. SCORE2-OP working group and ESC Cardiovascular risk collaboration; De Vries, T.I.; Cooney, M.T.; Selmer, R.M.; Hageman, S.H.J.; Pennells, L.A.; Wood, A.; Kaptoge, S.; Xu, Z.; Westerink, J.; et al. SCORE2-OP Risk Prediction Algorithms: Estimating Incident Cardiovascular Event Risk in Older Persons in Four Geographical Risk Regions. Eur. Heart J. 2021, 42, 2455–2467. [Google Scholar] [CrossRef]
  12. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration; Pennells, L.; Kaptoge, S.; Østergaard, H.B.; Read, S.H.; Carinci, F.; Franch-Nadal, J.; Petitjean, C.; Taylor, O.; Hageman, S.H.J.; et al. SCORE2-Diabetes: 10-Year Cardiovascular Risk Estimation in Type 2 Diabetes in Europe. Eur. Heart J. 2023, 44, 2544–2556. [Google Scholar] [CrossRef]
  13. Oldridge, N.; Höfer, S.; McGee, H.; Conroy, R.; Doyle, F.; Saner, H.; for the HeartQoL Project Investigators. The HeartQoL: Part I. Development of a New Core Health-Related Quality of Life Questionnaire for Patients with Ischemic Heart Disease. Eur. J. Prev. Cardiol. 2014, 21, 90–97. [Google Scholar] [CrossRef] [PubMed]
  14. Oldridge, N.; Höfer, S.; McGee, H.; Conroy, R.; Doyle, F.; Saner, H.; for the HeartQoL Project Investigators. The HeartQoL: Part II. Validation of a New Core Health-Related Quality of Life Questionnaire for Patients with Ischemic Heart Disease. Eur. J. Prev. Cardiol. 2014, 21, 98–106. [Google Scholar] [CrossRef] [PubMed]
  15. De Smedt, D.; Clays, E.; Höfer, S.; Oldridge, N.; Kotseva, K.; Maggioni, A.P.; Janssen, B.; De Bacquer, D.; EUROASPIRE Investigators. Validity and Reliability of the HeartQoL Questionnaire in a Large Sample of Stable Coronary Patients: The EUROASPIRE IV Study of the European Society of Cardiology. Eur. J. Prev. Cardiol. 2016, 23, 714–721. [Google Scholar] [CrossRef]
  16. Available online: https://www.who.int/News-Room/Fact-Sheets/Detail/Noncommunicable-Diseases (accessed on 30 December 2023).
  17. Roman, L. German Journal of Medicine Plasticity of Health. Plast. Health 2016, 1, 1–17. [Google Scholar] [CrossRef]
  18. Kubica, A.; Adamski, P.; Bączkowska, A.; Czarnecki, D.; Derewiecki, T.; Donderski, R.; Grzechowiak, E.; Jasiewicz, M.; Kleinrok, A.; Kozera, G.; et al. The Rationale for Multilevel EDucational and MOtivational Intervention in Patients after Myocardial infarcTION (MEDMOTION) Project Is to Support Multicentre Randomized Clinical Trial EvaLuating Safety and EffiCacy of Two TicagRelor-Based de-Escalation Ant. Med. Res. J. 2020, 5, 244–249. [Google Scholar] [CrossRef]
  19. Wang, J.; Wu, X.; Lai, W.; Long, E.; Zhang, X.; Li, W.; Zhu, Y.; Chen, C.; Zhong, X.; Liu, Z.; et al. Prevalence of Depression and Depressive Symptoms among Outpatients: A Systematic Review and Meta-Analysis. BMJ Open 2017, 7, e017173. [Google Scholar] [CrossRef]
  20. Juenger, J. Health Related Quality of Life in Patients with Congestive Heart Failure: Comparison with Other Chronic Diseases and Relation to Functional Variables. Heart 2002, 87, 235–241. [Google Scholar] [CrossRef]
  21. Jha, M.K.; Qamar, A.; Vaduganathan, M.; Charney, D.S.; Murrough, J.W. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019, 73, 1827–1845. [Google Scholar] [CrossRef]
  22. Vongmany, J.; Hickman, L.D.; Lewis, J.; Newton, P.J.; Phillips, J.L. Anxiety in Chronic Heart Failure and the Risk of Increased Hospitalisations and Mortality: A Systematic Review. Eur. J. Cardiovasc. Nurs. 2016, 15, 478–485. [Google Scholar] [CrossRef]
  23. Schroder, J.D.; Falqueto, H.; Mânica, A.; Zanini, D.; De Oliveira, T.; De Sá, C.A.; Cardoso, A.M.; Manfredi, L.H. Effects of Time-Restricted Feeding in Weight Loss, Metabolic Syndrome and Cardiovascular Risk in Obese Women. J. Transl. Med. 2021, 19, 3. [Google Scholar] [CrossRef]
  24. Akyuz, A. Exercise and Coronary Heart Disease. In Physical Exercise for Human Health; Xiao, J., Ed.; Advances in Experimental Medicine and Biology; Springer: Singapore, 2020; Volume 1228, pp. 169–179. ISBN 9789811517914. [Google Scholar]
  25. Acosta, S.; Johansson, A.; Drake, I. Diet and Lifestyle Factors and Risk of Atherosclerotic Cardiovascular Disease—A Prospective Cohort Study. Nutrients 2021, 13, 3822. [Google Scholar] [CrossRef] [PubMed]
  26. Moraes-Silva, I.C.; Rodrigues, B.; Coelho-Junior, H.J.; Feriani, D.J.; Irigoyen, M.-C. Myocardial Infarction and Exercise Training: Evidence from Basic Science. In Exercise for Cardiovascular Disease Prevention and Treatment; Xiao, J., Ed.; Advances in Experimental Medicine and Biology; Springer: Singapore, 2017; Volume 999, pp. 139–153. ISBN 978-981-10-4306-2. [Google Scholar]
  27. Uchmanowicz, I.; Lisiak, M.; Wleklik, M.; Gurowiec, P.; Kałużna–Oleksy, M. The Relationship between Frailty Syndrome and Quality of Life in Older Patients Following Acute Coronary Syndrome. Clin. Interv. Aging 2019, 14, 805–816. [Google Scholar] [CrossRef] [PubMed]
  28. Lourenço, E.; Sampaio, M.R.d.M.; Nzwalo, H.; Costa, E.I.; Ramos, J.L.S. Determinants of Quality of Life after Stroke in Southern Portugal: A Cross Sectional Community-Based Study. Brain Sci. 2021, 11, 1509. [Google Scholar] [CrossRef] [PubMed]
  29. Govindaraju, T.; McCaffrey, T.A.; McNeil, J.J.; Reid, C.M.; Smith, B.J.; Campbell, D.J.; Liew, D.; Owen, A.J. Quality of Life and Associations with Health-Related Behaviours among Older Adults with Increased Cardiovascular Risk. Nutr. Metab. Cardiovasc. Dis. 2022, 32, 1146–1153. [Google Scholar] [CrossRef] [PubMed]
  30. Palmiero, P.; Zito, A.; Maiello, M.; Cecere, A.; Mattioli, A.V.; Pedrinelli, R.; Scicchitano, P.; Ciccone, M.M. Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control. Curr. Hypertens. Rev. 2019, 15, 78–84. [Google Scholar] [CrossRef] [PubMed]
  31. Liang, H.; Luo, S.; Chen, X.; Lu, Y.; Liu, Z.; Wei, L. Effects of Tai Chi Exercise on Cardiovascular Disease Risk Factors and Quality of Life in Adults with Essential Hypertension: A Meta-Analysis. Heart Lung 2020, 49, 353–363. [Google Scholar] [CrossRef]
  32. Arija, V.; Villalobos, F.; Pedret, R.; Vinuesa, A.; Jovani, D.; Pascual, G.; Basora, J. Physical Activity, Cardiovascular Health, Quality of Life and Blood Pressure Control in Hypertensive Subjects: Randomized Clinical Trial. Health Qual. Life Outcomes 2018, 16, 184. [Google Scholar] [CrossRef]
  33. Yamaguchi, A. Influences of Quality of Life on Health and Well-Being. Soc. Indic. Res. 2015, 123, 77–102. [Google Scholar] [CrossRef]
  34. Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.; Biffi, A.; Boavida, J.-M.; Capodanno, D.; et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 2021, 42, 3227–3337. [Google Scholar] [CrossRef] [PubMed]
  35. Umphonsathien, M.; Rattanasian, P.; Lokattachariya, S.; Suansawang, W.; Boonyasuppayakorn, K.; Khovidhunkit, W. Effects of Intermittent Very-low Calorie Diet on Glycemic Control and Cardiovascular Risk Factors in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. J. Diabetes Investig. 2022, 13, 156–166. [Google Scholar] [CrossRef]
Figure 1. Mean quality of life assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with increasing total cardiovascular risk assessed with SCORE2 and SCORE2-OP algorithms.
Figure 1. Mean quality of life assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with increasing total cardiovascular risk assessed with SCORE2 and SCORE2-OP algorithms.
Jcdd 11 00045 g001
Figure 2. Mean quality of life assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with a decreasing number of controlled cardiovascular risk factors.
Figure 2. Mean quality of life assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with a decreasing number of controlled cardiovascular risk factors.
Jcdd 11 00045 g002
Figure 3. Mean quality of life assessed by HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with an increasing number of reported health-promoting behaviors undertaken.
Figure 3. Mean quality of life assessed by HeartQoL questionnaire (emotional and physical subscales and overall global score) in subgroups of patients with an increasing number of reported health-promoting behaviors undertaken.
Jcdd 11 00045 g003
Table 1. Socio-demographic and clinical characteristics of the study group—qualitative variables.
Table 1. Socio-demographic and clinical characteristics of the study group—qualitative variables.
Parameter Entire PopulationNon-Diabetic Population
N%N%
GenderMale6733.55433.3
Female13366.510866.7
Diseases for inclusion in the study:
Arterial hypertensionDiagnosed12763.511168.5
Diabetes mellitusDiagnosed3819.000
HypercholesterolemiaDiagnosed9045.07646.9
Controlled risk factors:
Non-smokerDeclared17085.013885.2
Systolic blood pressure<140 mmHg16180.513382.1
Diastolic blood pressure<90 mmHg17989.514690.1
Systolic/diastolic blood pressure<140 mmHg and <90 mmHg15577.512979.6
BMIUnderweight (<20.0 kg/m2)115.5116.8
Correct weight (20.0–24.9 kg/m2)7236.06238.3
Overweight (25.0–29.9 kg/m2)8442.06842.2
Obesity (≥30.0 kg/m2)3316.52113.0
Waist circumferenceNormal fat distribution (W < 80 cm, M < 94 cm)7437.06137.7
Moderate central fat accumulation (W ≥ 80 cm, M ≥ 94 cm)5728.54829.6
High central fat accumulation (W ≥ 88 cm, M ≥ 102 cm)6934.55332.7
Physical activityNo activity3015.02314.2
Low activity11055.08854.3
Regular activity6030.05131.5
Serum LDL-C concentration<2.6 mmol/L4623.03622.2
Serum TG concentration<1.7 mmol/L16381.513784.5
Fasting plasma glucose<5.56 mmol/L11758.510464.2
Number of controlled measures of CV risk factors021.010.6
152.531.9
2157.5116.8
34321.53320.4
45226.04024.7
53517.53219.8
63216.02716.7
7105.095.6
863.063.7
Number of reported health-promoting behaviors0168.0148.6
12512.52314.2
24321.53924.1
35929.54930.2
44522.53219.8
5126.053.1
Estimated cardiovascular risk (SCORE2 and SCORE2-OP)Low or moderateNANA9659.3
High NANA4125.3
Very highNANA2515.4
Note: NA—not applicable.
Table 2. Socio-demographic and clinical characteristics of the study group—quantitative variables.
Table 2. Socio-demographic and clinical characteristics of the study group—quantitative variables.
ParameterEntire Population
(N = 200)
Non-diabetic Population
(N = 162)
Mean
(±SD)
Median
(IQR)
Mean
(±SD)
Median
(IQR)
Age51.6
(±13.6)
52.0
(43.0–60.5)
50.4
(±13.6)
51.0
(41–59)
Systolic blood pressure (mmHg)127.2
(±14.5)
125.0
(118.0–135.0)
126.6
(±14.0)
125.0
(118.0–134.0)
Diastolic blood pressure (mmHg)76.5
(±9.3)
77.5
(70.0–82.0)
76.4
(±9.1)
76.0
(70.0–82.0)
Waist circumference (cm)88.0
(±12.2)
87.0
(80.0–95.5)
87.2
(±11.9)
86.0
(79.0–94.0)
BMI (kg/m2)26.4
(±4.1)
26.0
(23.9–28.7)
26.0
(±3.7)
25.9
(23.9–28.1)
Serum total cholesterol concentration (mmol/L)5.6
(±1.1)
5.6
(4.9–6.3)
5.6
(±1.0)
5.6
(5.0–6.2)
Serum HDL-C concentration (mmol/L)1.6
(±0.4)
1.5
(1.3–1.8)
1.6
(±0.4)
1.5
(1.3–1.8)
Serum non-HDL-C concentration (mmol/L)4.1
(±1.0)
4.0
(3.4–4.7)
4.0
(±1)
4.0
(3.3–4.6)
Serum LDL-C concentration (mmol/L)3.3
(±1.0)
3.3
(2.7–4)
3.3
(±0.9)
3.3
(2.7–4)
Serum TG concentration (mmol/L)1.4
(±0.8)
1.2
(0.9–1.6)
1.3
(±0.8)
1.2
(0.9–1.5)
Fasting plasma glucose (mmol/L)6.0
(±1.2)
5.9
(5.4–6.4)
5.8
(±0.8)
5.8
(5.4–6.2)
Table 3. Mean quality of life in relation to the control of individual risk factors assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score).
Table 3. Mean quality of life in relation to the control of individual risk factors assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score).
Controlled Risk FactorsAchieving ControlNHeartQoL EmotionalHeartQoL PhysicalHeartQoL Global
Mean (±SD)pMean (±SD)pMean (±SD)p
Ideal blood pressureNo452.24 (±0.66)0.01172.54 (±0.58)0.00022.46 (±0.53)0.0002
Yes1552.48 (±0.66)2.79 (±0.47)2.71 (±0.47)
Ideal waist circumferenceNo1262.33 (±0.71)0.01232.67 (±0.56)0.00832.57 (±0.53)0.0026
Yes742.6 (±0.54)2.85 (±0.36)2.78 (±0.37)
Ideal BMINo1182.42 (±0.65)0.61292.71 (±0.54)0.80322.63 (±0.52)0.5849
Yes722.44 (±0.69)2.76 (±0.46)2.67 (±0.46)
Normal LDL cholesterol levelNo1542.42 (±0.67)0.74042.73 (±0.52)0.65332.64 (±0.5)0.7718
Yes462.46 (±0.65)2.76 (±0.45)2.68 (±0.47)
Normal triglyceride levelsNo372.36 (±0.61)0.29122.80 (±0.33)0.76552.68 (±0.34)0.3786
Yes1632.44 (±0.68)2.72 (±0.53)2.64 (±0.52)
Normal fasting glucoseNo832.3 (±0.67)0.00562.68 (±0.50)0.00662.57 (±0.48)0.0013
Yes1172.53 (±0.65)2.78 (±0.51)2.71 (±0.49)
Non-smokerNo302.36 (±0.82)0.91512.62 (±0.55)0.24512.55 (±0.59)0.6226
Yes1702.44 (±0.63)2.76 (±0.49)2.67 (±0.47)
Regular physical activityNo1402.34 (±0.69)0.00292.66 (±0.55)<0.00012.57 (±0.53)0.0001
Yes602.64 (±0.54)2.92 (±0.30)2.84 (±0.30)
Table 4. Mean quality of life in relation to the individual health-promoting behaviors undertaken, as assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score).
Table 4. Mean quality of life in relation to the individual health-promoting behaviors undertaken, as assessed by the HeartQoL questionnaire (emotional and physical subscales and overall global score).
Health-Promoting BehaviorDeclaredNHeartQoL EmotionalHeartQoL PhysicalHeartQoL Global
Mean (±SD)pMean (±SD)pMean (±SD)p
Dietary changes No392.30 (±0.69)0.11562.66 (±0.45)0.02692.56 (±0.47)0.0399
Yes1612.46 (±0.66)2.76 (±0.51)2.68 (±0.43)
Weight reductionNo982.40 (±0.71)0.74392.71 (±0.55)0.99892.62 (±0.54)0.9989
Yes1022.46 (±0.62)2.77 (±0.46)2.68 (±0.43)
Increased physical activityNo562.25 (±0.69)0.00852.58 (±0.58)0.00112.48 (±0.55)0.0014
Yes1442.50 (±0.64)2.88 (±0.46)2.71 (±0.45)
Smoking cessationNo102.28 (±0.97)0.76012.29 (±0.89)0.20202.29 (±0.85)0.6115
Yes632.26 (±0.73)2.67 (±0.51)2.55 (±0.51)
Decreased alcohol consumptionNo1422.51 (±0.64)0.00962.75 (±0.49)0.13922.68 (±0.47)0.0525
Yes582.25 (±0.70)2.70 (±0.55)2.57 (±0.53)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kosobucka-Ozdoba, A.; Pietrzykowski, Ł.; Michalski, P.; Ratajczak, J.; Grzelakowska, K.; Kasprzak, M.; Kubica, J.; Kubica, A. Achieving Cardiovascular Risk Management Goals and Patient Quality of Life. J. Cardiovasc. Dev. Dis. 2024, 11, 45. https://doi.org/10.3390/jcdd11020045

AMA Style

Kosobucka-Ozdoba A, Pietrzykowski Ł, Michalski P, Ratajczak J, Grzelakowska K, Kasprzak M, Kubica J, Kubica A. Achieving Cardiovascular Risk Management Goals and Patient Quality of Life. Journal of Cardiovascular Development and Disease. 2024; 11(2):45. https://doi.org/10.3390/jcdd11020045

Chicago/Turabian Style

Kosobucka-Ozdoba, Agata, Łukasz Pietrzykowski, Piotr Michalski, Jakub Ratajczak, Klaudyna Grzelakowska, Michał Kasprzak, Jacek Kubica, and Aldona Kubica. 2024. "Achieving Cardiovascular Risk Management Goals and Patient Quality of Life" Journal of Cardiovascular Development and Disease 11, no. 2: 45. https://doi.org/10.3390/jcdd11020045

APA Style

Kosobucka-Ozdoba, A., Pietrzykowski, Ł., Michalski, P., Ratajczak, J., Grzelakowska, K., Kasprzak, M., Kubica, J., & Kubica, A. (2024). Achieving Cardiovascular Risk Management Goals and Patient Quality of Life. Journal of Cardiovascular Development and Disease, 11(2), 45. https://doi.org/10.3390/jcdd11020045

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop